Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Subcutaneous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Bosnia | Brazil | Croatia | India | Ireland | Taiwan | Thailand | Turkey | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: M.D. Anderson Cancer Center
Company Location: Western America
Company Founding Year: 1941
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes|Vision, Low|Renal Transplant|Other|Epilepsy
Phase 2: Hereditary Sensory and Autonomic Neuropathies|Acute Myeloid Leukemia|Peripheral Nervous System Diseases|Amyotrophic Lateral Sclerosis|Carcinoma, Merkel Cell|Acute Monocytic Leukemia|Preleukemia|Chronic Myeloid Leukemia|Adenocarcinoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Non-Small-Cell Lung Cancer|Acute Megakaryoblastic Leukemia|Chronic Myelomonocytic Leukemia|Pleural Cancer|Mesothelioma|Blast Crisis|Juvenile Myelomonocytic Leukemia,|Myeloid, Accelerated Leukemia|Acute Myelomonocytic Leukemia|Acute Erythroblastic Leukemia|Alzheimer Disease|Pancreatic Cancer
Phase 1: Stem Cell Transplant|Graft vs Host Disease|Sarcoma|Pancreatic Cancer|Cervical Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma|Renal Cell Carcinoma|Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified|Uterine Cancer|Adenocarcinoma|Melanoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2400089707 |
ChiCTR2400089707 | N/A |
Not yet recruiting |
Kidney Diseases |
2026-01-01 |
|||
ACTRN12619000561189 |
ACTRN12619000561189 | N/A |
Recruiting |
Hereditary Sensory Neuropathy Type 1 |
2024-12-31 |
2026-02-15 |
||
NCT06377631 |
FATHIS+ | N/A |
Completed |
Liver Diseases, Alcoholic|Obesity, Abdominal|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease |
2025-04-08 |
2025-04-18 |
||
NCT05807204 |
FATHIS | N/A |
Completed |
Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic|Obesity, Abdominal|Liver Diseases, Alcoholic |
2023-12-20 |
2024-02-24 |
||
NCT04646447 |
PIC-29-20 | N/A |
Unknown status |
Brain Diseases |
2021-08-31 |
2022-11-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT02528994 |
2014D001170 | N/A |
Withdrawn |
Hypertension|Type 2 Diabetes |
2016-09-01 |
2019-03-20 |
||
NCT06626256 |
NCI-2024-08121 | P1 |
Withdrawn |
Pancreatic Cancer|Cervical Cancer|Uterine Cancer|Melanoma|Pancreatic Ductal Carcinoma|Adenocarcinoma|Renal Cell Carcinoma|Colorectal Cancer |
2027-10-30 |
2025-12-25 |
||
NCT03240861 |
NYESO SCT | P1 |
Terminated |
Sarcoma |
2023-10-19 |
2023-11-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02774291 |
NCI-2015-01781 | P1 |
Terminated |
Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified |
2020-07-01 |
2023-08-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT01630564 |
NCI-2013-00385 | P1 |
Terminated |
Stem Cell Transplant|Graft vs Host Disease |
2018-05-30 |
2019-03-19 |
Treatments |
|
NCT06113055 |
SENSE | P2 |
Unknown status |
Hereditary Sensory and Autonomic Neuropathies |
2025-08-01 |
2025-11-01 |
Primary Endpoints|Treatments|Trial Status |
|
NCT03580616 |
ALS | P2 |
Terminated |
Amyotrophic Lateral Sclerosis |
2022-08-03 |
2023-05-10 |
Primary Endpoints|Treatments |
|
NCT01823198 |
NCI-2013-00993 | P2 |
Completed |
Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Acute Erythroblastic Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Acute Myelomonocytic Leukemia|Blast Crisis|Myeloid, Accelerated Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Preleukemia|Chronic Myeloid Leukemia |
2022-05-10 |
2022-06-01 |
Primary Endpoints |
|
NCT03062449 |
LSPI-2 | P2 |
Terminated |
Alzheimer Disease |
2021-07-20 |
2024-07-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02620865 |
NCI-2015-01942 | P2 |
Completed |
Pancreatic Cancer|Adenocarcinoma |
2021-06-21 |
2025-02-07 |
||
NCT02408016 |
NCI-2015-00329 | P2 |
Terminated |
Mesothelioma|Pleural Cancer|Non-Small-Cell Lung Cancer |
2020-06-30 |
2022-04-06 |
Primary Endpoints|Treatments |
|
NCT02770820 |
NCI-2016-00042 | P2 |
Terminated |
Acute Myeloid Leukemia |
2020-06-01 |
2022-04-06 |
Primary Endpoints |
|
NCT01640301 |
NCI-2011-03362 | P2 |
Terminated |
Acute Myeloid Leukemia |
2020-03-20 |
2022-06-24 |
Primary Endpoints |
|
NCT01835782 |
L-Serine2013 | P2 |
Unknown status |
Amyotrophic Lateral Sclerosis |
2016-12-01 |
2019-03-19 |
Treatments |
|
NCT01733407 |
FD-R-04127-01 | P2 |
Completed |
Peripheral Nervous System Diseases|Hereditary Sensory and Autonomic Neuropathies |
2016-05-01 |
2019-03-19 |
Treatments |
|
NCT01758458 |
NCI-2012-02779 | P2 |
Terminated |
Carcinoma, Merkel Cell |
2016-05-01 |
2022-04-06 |
Primary Endpoints|Treatments |
|
NCT07342439 |
SEErine | P3 |
Not yet recruiting |
Type 2 Diabetes|Vision, Low |
2029-11-01 |
2026-01-16 |
Primary Endpoints |
|
NCT07377032 |
TAP-GRIN | P3 |
Recruiting |
Epilepsy |
2028-06-01 |
2026-01-30 |
Primary Endpoints|Treatments |
|
2024-519757-11-00 |
RR-DVIVO | P3 |
Not yet recruiting |
Renal Transplant |
2027-12-31 |
2025-05-02 |
Treatments |
|
2022-000241-32 |
2022-000241-32 | P3 |
Completed |
Other |
2024-03-26 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/15/2024 |
PubMed |
The truncated AXIN1 isoform promotes hepatocellular carcinoma metastasis through SRSF9-mediated exon 9 skipping. |
|
05/15/2024 |
PubMed |
Exploration of three Dyadobacter fermentans enzymes uncovers molecular activity determinants in CE15. |
|
05/14/2024 |
PubMed |
SPINK4 modulates inhibition of glycolysis against colorectal cancer progression. |
|
10/03/2023 |
News Article |
Crickets Market [2023-2031] Size Is Set to Grow At A Remarkable Pace in the Coming Years |
|
09/28/2023 |
News Article |
Serine Market Share, Types, Applications, Products, Size, Growth, Insights and Forecasts Report 2029 |
|
09/04/2023 |
News Article |
Security System Integrators Market Size 2023 Booming Worldwide by 2031 |
|
01/31/2022 |
News Article |
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients |